Contains 0.3mg/ml of the main ingredient "bimaprost"

  • Glaucoma treatment eye drops

  • It works to reduce intraocular pressure
    Ocular hypertension treatment

  • Eyelash growth
    The effect of hair growth

  • Domestic release
    Glash Vista and
    Same ingredients

Lumigan Ophthalmic Solution

Lumigan Solution

Manufacturer information: Allergan / Contents: 3ml

Product Description

The bimaprost contained in Lumigan Solution works to lower intraocular pressure and is used to treat glaucoma and ocular hypertension.

How to use

When used as a treatment for glaucoma
Apply 1 drop to your eye, once daily.

When used to promote eyelash growth and thickening
Apply to the base of your eyelashes once a day before going to bed.

Ingredients

Bimatoprost 0.3mg/ml(0.03%)
Benzalkonium Chloride 0.05mg/ml

    Usage notes

    Use within 30 days after opening.
    Lumigan Solution is an eye drop for treating glaucoma, but if you are using it for eyelash growth, never apply it as an eye drop and be careful not to get the liquid in your eyes.
    Also, be careful not to get the liquid on your skin.
    After applying the liquid to the base of your eyelashes, wipe off any excess liquid on your skin.
    Be sure to consult your doctor before using this product.

    Product Features

    The U.S. Food and Drug Administration
    FDA approved eye drops for glaucoma treatment

    Allergan's Lumigan Solution contains bimaprost as its main ingredient and is approved by the U.S. Food and Drug Administration.FDA approved eye drops for glaucoma treatmentis.
    Bimaprost, the main ingredient in Lumigan Solution, works to lower intraocular pressure and is used to treat glaucoma and ocular hypertension.

    In addition, the main ingredient, bimaprost, can cause eyelash problems if the liquid gets on the base of the eyelashes.The effect of eyelash growth and thickening can be seen.
    As a side effect of bimaprost has been found to cause eyelash growth and thickening, it has also attracted attention as an eyelash growth agent, and Latisse, which uses the same ingredient (main ingredient) bimaprost, has been released.
    In Japan, Allergan Japan has marketed it under the name "Glash Vista," the first drug in the country to receive manufacturing and sales approval from the Ministry of Health, Labor and Welfare as a medical drug.

    TOP
    en_USEnglish
    jaJapanese en_USEnglish